Finally, the administration of drugs during high-risk pregnancies (i.e., when IUGR is demonstrated) is another potential measure: sildenafil has been investigated but increased fetal death in a clinical trial has led to discontinuation of the study [90]; vascular endothelial growth factor is currently under investigation to promote angiogenesis [91], insulin-like growth factor 1 (IGF-1), antioxidants and melatonin have been tested in preclinical studies [92,93,94]. This evidence concerns the gene IGF1 and fetal growth restriction.